Celsion Corp. (CLSN) presented findings from its Phase Ib OVATION Study at the ASCO 2017 Annual Meeting over the weekend. Dr. Premal Thaker stated that they have "seen highly promising clinical findings including a patient with a complete pathological response along with a very high rate of R0 at time of debulking surgery."
from RTT - Before the Bell http://ift.tt/2rZQCTA
via IFTTT
No comments:
Post a Comment